[go: up one dir, main page]

MX2021003030A - Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. - Google Patents

Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.

Info

Publication number
MX2021003030A
MX2021003030A MX2021003030A MX2021003030A MX2021003030A MX 2021003030 A MX2021003030 A MX 2021003030A MX 2021003030 A MX2021003030 A MX 2021003030A MX 2021003030 A MX2021003030 A MX 2021003030A MX 2021003030 A MX2021003030 A MX 2021003030A
Authority
MX
Mexico
Prior art keywords
treatment
joint pain
pharmaceutical compositions
compositions suitable
articular delivery
Prior art date
Application number
MX2021003030A
Other languages
English (en)
Inventor
Yun- Long Tseng
Sheue- Fang SHIH
Po- Chun CHANG
Lo Chang
Original Assignee
Tlc Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tlc Biopharmaceuticals Inc filed Critical Tlc Biopharmaceuticals Inc
Publication of MX2021003030A publication Critical patent/MX2021003030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a composición farmacéutica para el tratamiento de dolor de articulación; la composición contiene una mezcla de lípidos que contiene uno o más fosfolípidos; y una cantidad efectiva de un agente terapéutico o una sal farmacéuticamente aceptable del mismo, en donde la cantidad total de fosfolípidos en la composición es aproximadamente 20 mM a aproximadamente 150 mM, opcionalmente 70 mM a 110 mM; también se proporciona el uso de la composición farmacéutica en el tratamiento de dolor de articulación por inyección articular.
MX2021003030A 2018-09-16 2019-09-16 Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. MX2021003030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16
PCT/US2019/051247 WO2020056399A1 (en) 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Publications (1)

Publication Number Publication Date
MX2021003030A true MX2021003030A (es) 2021-05-27

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003030A MX2021003030A (es) 2018-09-16 2019-09-16 Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.

Country Status (15)

Country Link
US (1) US12208104B2 (es)
EP (1) EP3849522A1 (es)
JP (1) JP7634476B2 (es)
KR (1) KR20210060559A (es)
CN (1) CN112702993A (es)
AU (1) AU2019339528B2 (es)
BR (1) BR112021004880A2 (es)
CA (1) CA3112234A1 (es)
CL (1) CL2021000627A1 (es)
IL (1) IL281513A (es)
MX (1) MX2021003030A (es)
SG (1) SG11202102400PA (es)
TW (1) TWI843751B (es)
WO (1) WO2020056399A1 (es)
ZA (1) ZA202101688B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021320774A1 (en) 2020-08-05 2023-03-09 Tlc Biopharmaceuticals, Inc. Pharmaceutical composition of intra-articular corticosteroid for pain control
WO2024230404A1 (zh) * 2023-05-05 2024-11-14 中南大学湘雅医院 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用
TW202519194A (zh) * 2023-11-03 2025-05-16 台灣微脂體股份有限公司 用於疼痛控制之關節內皮質類固醇的微脂體組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
EP1371362A1 (en) 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
PT2797601T (pt) 2012-02-10 2018-06-27 Taiwan Liposome Co Ltd Composições farmacêuticas para reduzir complicações de esteroide ocular
US9789062B2 (en) 2012-07-05 2017-10-17 Tlc Biopharmaceuticals, Inc. Methods of treating arthritis

Also Published As

Publication number Publication date
AU2019339528B2 (en) 2025-01-30
BR112021004880A2 (pt) 2021-06-01
KR20210060559A (ko) 2021-05-26
IL281513A (en) 2021-04-29
TWI843751B (zh) 2024-06-01
TW202023569A (zh) 2020-07-01
US12208104B2 (en) 2025-01-28
JP7634476B2 (ja) 2025-02-21
EP3849522A1 (en) 2021-07-21
JP2022500364A (ja) 2022-01-04
WO2020056399A1 (en) 2020-03-19
CN112702993A (zh) 2021-04-23
ZA202101688B (en) 2024-06-26
AU2019339528A1 (en) 2021-04-15
CA3112234A1 (en) 2020-03-19
CL2021000627A1 (es) 2021-09-10
US20210338688A1 (en) 2021-11-04
SG11202102400PA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
PE20242299A1 (es) Composiciones agonistas de gip/glp1
MX2024001203A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con moduladores metabolicos para usarse en tratar enfermedades del higado graso.
MX2025004156A (es) Composiciones topicas para el alivio del dolor.
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
AR063782A1 (es) Parche y metodo transdermico para emesis
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
PH12021553056A1 (en) Modified release formulations and uses thereof
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
DOP2022000107A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
AR127966A1 (es) Formulaciones tópicas de inhibidores de pi3k-delta
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
MX2021013347A (es) Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.
AR120453A1 (es) Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
MX2020009645A (es) Inhibidores de secrecion de proteinas basados en triazaciclododecansulfonamida ("tcd").
CO2018009584A2 (es) Composición anestésica tópica